Erlotinib

Erlotinib Reactions 1680, p130 - 2 Dec 2017 Hepatotoxicity: case report A 80-year-old woman developed hepatotoxicity during treatment with erlotinib [route not stated]. The woman, who had a history of stage IV lung adenocarcinoma, started receiving treatment with erlotinib 150mg daily in December 2015. After four days of initiation of erlotinib, she experienced an increase in total bilirubin level to 2.5 mg/dL. She was deemed to have developed grade 2 hepatotoxicity that was induced by erlotinib. The treatment with erlotinib was temporarily stopped. In January 2016, erlotinib was restarted. In February 2016, the dose was adjusted to 100mg every other day and total bilirubin level was carefully monitored. However, her serum total bilirubin increased to 2.7 mg/dL (peak level) at a dose of 75mg every other day. Hence, the dose was reduced to 50mg every other day. Subsequently, in May 2016, treatment with erlotinib was discontinued and was switched to afatinib. Her underlined condition showed radiological resolution at 1 month after the initiation of afatinib, without further increase in the bilirubin level. Author comment: "Our results indicate that afatinib is an important treatment option when erlotinib-induced hepatotoxicity develops, regardless of the patients’ age." Yamanaka Y, et al. Afatinib therapy for brain metastases aggravated by a reduction in the dose of erlotinib due to the development of hepatotoxicity. Internal Medicine 56: 2895-2898, No. 21, 2017. Available from: URL: http://doi.org/10.2169/ internalmedicine.8638-16 - Japan 803284478 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Erlotinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/erlotinib-WwXvmwZzpr
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39061-5
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial